MacroGenics and EVERSANA Announce Agreement to Support the Potential Launch and Commercialization of Margetuximab

ROCKVILLE, MD and CHICAGO, IL, Nov. 30, 2020 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that it has partnered with EVERSANA, a pioneer of next-generation commercial services to the global life sciences industry, to commercialize margetuximab in the United States, if approved.

Continue reading here:
MacroGenics and EVERSANA Announce Agreement to Support the Potential Launch and Commercialization of Margetuximab

Related Posts